{"disease":{"id":"solid-malignancies","name":"solid malignancies"},"drugs":{"marketed":[{"drug_id":"dactinomycin","indication_name":"Locally Recurrent or Locoregional Solid Malignancies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cosmegen","generic_name":"DACTINOMYCIN","company_name":"Recordati","drug_phase":"marketed","molecular_target":"DNA","drug_class":"Actinomycin [EPC]","quality_score":65,"revenue":null,"mechanism":"Dactinomycin binds DNA and inhibits RNA synthesis, demonstrating cytotoxic activity in cancer models."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05148806","title":"Mass Evaluation of Lateral Flow Immunoassays for the Detection of SARS-CoV-2 (Covid-19) Antibodies","phase":"","overall_status":"COMPLETED","enrollment_count":28411,"lead_sponsor_name":"Imperial College London","has_results":true},{"nct_id":"NCT02457962","title":"Mayo Clinic Radiotherapy Patient Outcomes Registry and Biobanking Study","phase":"","overall_status":"RECRUITING","enrollment_count":15000,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT03486873","title":"Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":3500,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT07303387","title":"Efficacy and Safety of the Valemetostat in Patients With Selected Solid Tumors.","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":900,"lead_sponsor_name":"Gustave Roussy, Cancer Campus, Grand Paris","has_results":false},{"nct_id":"NCT03084471","title":"An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":867,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT05417594","title":"Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":695,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04389541","title":"Clinical Research Platform on Decision Making and Clinical Impact of Biomarker-Driven Precision Oncology","phase":"","overall_status":"COMPLETED","enrollment_count":499,"lead_sponsor_name":"iOMEDICO AG","has_results":false},{"nct_id":"NCT02740985","title":"A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":313,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT07136779","title":"First-in-Human Trial of VBC101 in Participants With Advanced Solid Tumor Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":310,"lead_sponsor_name":"VelaVigo Bio Inc","has_results":false},{"nct_id":"NCT04905329","title":"A Multicenter Prospective Post-registration Study of Empegfilgrastim to Evaluate Safety and Efficacy in Special Cancer Populations","phase":"","overall_status":"UNKNOWN","enrollment_count":285,"lead_sponsor_name":"Moscow Clinical Scientific Center","has_results":false},{"nct_id":"NCT07195916","title":"A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":280,"lead_sponsor_name":"Incyte Corporation","has_results":false},{"nct_id":"NCT05315167","title":"A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects with Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":267,"lead_sponsor_name":"Zhuhai Yufan Biotechnologies Co., Ltd","has_results":false},{"nct_id":"NCT07299747","title":"Clinical Trial of VBC103 in Patients With Advanced Malignant Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":255,"lead_sponsor_name":"VelaVigo Bio Inc","has_results":false},{"nct_id":"NCT05735275","title":"A Phase 1 Study of SHR-A2102 in Subjects With Advanced Solid Tumors.","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":252,"lead_sponsor_name":"Shanghai Hengrui Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT07223047","title":"A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":252,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT07167381","title":"xDRIVE for Florida-based Cancer Patients","phase":"NA","overall_status":"RECRUITING","enrollment_count":210,"lead_sponsor_name":"First Ascent Biomedical Inc.","has_results":false},{"nct_id":"NCT07181473","title":"A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Phrontline Biopharma","has_results":false},{"nct_id":"NCT01058707","title":"Dose Escalation Study of MLN0128 in Participants With Advanced Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":198,"lead_sponsor_name":"Millennium Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT07174453","title":"Trial to Evaluate irAEs With Different Standard of Care Dosing Strategies of Standard of Care Immunotherapies","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":192,"lead_sponsor_name":"University of Kansas Medical Center","has_results":false},{"nct_id":"NCT02325739","title":"FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":172,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT05028478","title":"A Study of CN202 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":164,"lead_sponsor_name":"Curon Biopharmaceutical (Australia) Co Pty Ltd","has_results":false},{"nct_id":"NCT02537418","title":"Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":153,"lead_sponsor_name":"Canadian Cancer Trials Group","has_results":false},{"nct_id":"NCT03082209","title":"A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":153,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT07390838","title":"A Study of SH009 Injection in Patients With Advanced Solid Tumors.","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"Nanjing Sanhome Pharmaceutical, Co., Ltd.","has_results":false},{"nct_id":"NCT05690581","title":"Safety, Tolerability, Pharmacokinetic Characteristics, and Efficacy of CM369 in Advanced Solid Tumors & Hematologic Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":146,"lead_sponsor_name":"Beijing InnoCare Pharma Tech Co., Ltd.","has_results":false},{"nct_id":"NCT02000934","title":"A Study of TAK-659 in Adult Participants With Advanced Solid Tumor and Lymphoma Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":143,"lead_sponsor_name":"Calithera Biosciences, Inc","has_results":false},{"nct_id":"NCT03739931","title":"Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":134,"lead_sponsor_name":"ModernaTX, Inc.","has_results":false},{"nct_id":"NCT06720987","title":"A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":128,"lead_sponsor_name":"Kumquat Biosciences Inc.","has_results":false},{"nct_id":"NCT03363893","title":"Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":124,"lead_sponsor_name":"Carrick Therapeutics Limited","has_results":false},{"nct_id":"NCT05023486","title":"NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":121,"lead_sponsor_name":"Novita Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT05306509","title":"Nurse-initiated Conversations for Early Integration of Palliative Care in Pediatric Oncology","phase":"NA","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"Children's Hospital of Fudan University","has_results":false},{"nct_id":"NCT06224855","title":"A Study of DXC006 in Patients With Advanced Solid Tumors and Hematologic Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":110,"lead_sponsor_name":"Hangzhou DAC Biotechnology Co., Ltd.","has_results":false},{"nct_id":"NCT01885195","title":"MEK162 for Patients With RAS/RAF/MEK Activated Tumors","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":110,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT07155811","title":"Lymphocyte Function Testing in Immuno-oncology","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Centre Leon Berard","has_results":false},{"nct_id":"NCT06649708","title":"HX044,FIH Study in Patients with Advanced Solid Tumor Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd.","has_results":false},{"nct_id":"NCT07476534","title":"Exploration Study of Molecular Biomarkers for Tumor-related Anxiety and Depression","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":100,"lead_sponsor_name":"The First Affiliated Hospital of Xinxiang Medical College","has_results":false},{"nct_id":"NCT00979134","title":"Study is Designed to Assess the Safety and Tolerability of AZD4547 at Increasing Doses in Patients With Advanced Tumours","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":95,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT03386526","title":"APG-1387 in Patients With Advanced Solid Tumors or Hematologic Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":90,"lead_sponsor_name":"Ascentage Pharma Group Inc.","has_results":false},{"nct_id":"NCT06136884","title":"A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors With or Without Brain Metastases","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":86,"lead_sponsor_name":"A2A Pharmaceuticals Inc.","has_results":false},{"nct_id":"NCT02160041","title":"BGJ398 for Patients With Tumors With FGFR Genetic Alterations","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":84,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT06994806","title":"A Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":84,"lead_sponsor_name":"Kumquat Biosciences Inc.","has_results":false},{"nct_id":"NCT02265510","title":"An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":83,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT03323398","title":"Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":79,"lead_sponsor_name":"ModernaTX, Inc.","has_results":true},{"nct_id":"NCT02298387","title":"A Phase 1 Study of OMP-305B83 in Subjects With Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":71,"lead_sponsor_name":"OncoMed Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT02959437","title":"Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":70,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT01351350","title":"Dose Escalation Study of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":68,"lead_sponsor_name":"Millennium Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT02141347","title":"Ph1 to Assess Safety, Tolerability of Tremelimumab/ Tremelimumab+MEDI4736 in Japanese Solid Malignancies/ Mesothelioma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":65,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04136834","title":"A Phase I Open-label Study for Subjects With Advanced Malignancies","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":62,"lead_sponsor_name":"Athenex, Inc.","has_results":false},{"nct_id":"NCT07363967","title":"A Phase I First-in-Human Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of SWA1211 Tablets in Subjects With Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Beijing StoneWise Technology Co., Ltd","has_results":false},{"nct_id":"NCT04989387","title":"Study of INCA 0186 in Subjects With Advanced Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":57,"lead_sponsor_name":"Incyte Corporation","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}